These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 17020988

  • 1. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S.
    Clin Cancer Res; 2006 Oct 01; 12(19):5809-16. PubMed ID: 17020988
    [Abstract] [Full Text] [Related]

  • 2. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.
    J Clin Oncol; 2008 Jan 10; 26(2):196-203. PubMed ID: 18182662
    [Abstract] [Full Text] [Related]

  • 3. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A, Lazarus HM, Hartman P, Jacobberger JW, Whitacre C, Gerson SL, Ksenich P, Cooper BW, Frisa PS, Gottlieb M, Murgo AJ, Remick SC.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM.
    Clin Cancer Res; 2000 Mar 01; 6(3):825-8. PubMed ID: 10741703
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul 01; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF.
    Cancer; 2004 May 15; 100(10):2181-9. PubMed ID: 15139062
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC.
    Clin Cancer Res; 2005 Dec 01; 11(23):8413-7. PubMed ID: 16322303
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH.
    J Clin Oncol; 2005 Feb 01; 23(4):694-704. PubMed ID: 15681517
    [Abstract] [Full Text] [Related]

  • 17. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianní L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S.
    Cancer; 2005 Dec 15; 104(12):2743-52. PubMed ID: 16284990
    [Abstract] [Full Text] [Related]

  • 18. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
    Alas S, Bonavida B, Emmanouilides C.
    Anticancer Res; 2000 Dec 15; 20(5A):2961-6. PubMed ID: 11062708
    [Abstract] [Full Text] [Related]

  • 19. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 20. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM.
    Clin Cancer Res; 1998 Feb 01; 4(2):445-53. PubMed ID: 9516935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.